RxDoctor Payments Data

Bisher Mustafa, MD

Internal Medicine · Huntington, WVNPI 1205361292

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $25,425 of the $28,196 with a category attached, or 90.2%. Lilly USA, LLC accounts for 98.7% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $27,728, more than ten times the $84 reported in 2019. Among internal medicine clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$28,196in general payments, 2019–2025

Across 61 payments — averaging $462.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$28K
  • Novo Nordisk$100
  • Amgen$84
  • Phathom Pharmaceuticals, Inc.$57
  • Sanofi$35
  • Paratek Pharmaceuticals, Inc.$22
  • plus $71 from 4 others

What the payments were for

  • Speaking & faculty fees$25,42590%
  • Travel & lodging$1,6256%
  • Food & beverage$1,1474%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,196 in reported general payments places this provider in the 95th percentile of 573 internal medicine providers in West Virginia.

See all internal medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$167,820
Medicare patients
399
Services billed
1,993

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide164$266,759
MounjaroTirzepatide165$213,365
EliquisApixaban45$60,095
JardianceEmpagliflozin15$24,109
WegovySemaglutide16$21,096
Victoza 3-PakLiraglutide23$17,730
XareltoRivaroxaban23$16,800
TradjentaLinagliptin13$13,693
Clobetasol Propionate13$2,401
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen74$2,358
Dexlansoprazole DrDexlansoprazole12$1,936
Topiramate111$1,556
Gabapentin96$1,048
Albuterol Sulfate HfaAlbuterol Sulfate27$936
Ultra-Fine Nano Pen NeedlePen Needle, Diabetic15$869

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$100$287,854180 claims
Lilly USA, LLCMounjaro$27,829$213,365165 claims
Johnson & JohnsonXarelto$12$16,80023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 573 internal medicine providers in West Virginia.

Other internal medicine in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →